Gas6 and Soluble MerTK in Periodontal Diseases
ConditionPeriodontitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAbant Izzet Baysal University
About this trial
This study aimed to investigate gingival crevicular fluid (GCF) and serum soluble MerTK (sMerTK) and Gas6 levels in periodontal health and disease. A total of 90 individuals, 30 patients with stage III grade B periodontitis, 30 with gingivitis and 30 periodontally healthy individuals were included. Whole-mouth and site-specific clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index, plaque index were recorded. GCF and serum sMerTK and Gas6 levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by using non-parametric tests.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals without systemic diseases that may affect periodontal tissues (such as cardiovascular diseases, atherosclerosis, immune system disorders, rheumatoid arthritis, obesity, cancer, and diabetes)
Individuals who have not used antibiotics within the last 3 months
Individuals not taking any medications known to affect periodontal tissues
Individuals without infectious diseases such as HIV, hepatitis B virus (HBV), or tuberculosis
Disqualifiers
Pregnant or lactating individuals
Individuals who have received periodontal treatment within the last 6 months
Current smokers
Trial population
This clinical study will be conducted on individuals who apply to the Department of Periodontology, Faculty of Dentistry, Abant İzzet Baysal University.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
gingival crevicular fluid collection
Other interventionGingival crevicular fluid collection using sterile paper strips inserted into the gingival sulcus for 30 seconds from selected periodontal sites (healthy, gingivitis, and periodontitis) for biomarker analysis (Gas6 and sMerTK).
Treatment groups
90 Participants
are divided into 3 treatment groupsGroup A: periodontally healthy (H) group1 intervention
Group B: gingivitis (G) group1 intervention
Group C: stage III grade B periodontitis (P) group1 intervention
Trial outcomes
Primary outcomes
1
Gas6 Levels in Gingival Crevicular Fluid
Quantitative measurement of Gas6 levels (pg/mL) in gingival crevicular fluid samples using enzyme-linked immunosorbent assay (ELISA), and comparison of these levels among periodontally healthy, gingivitis, and periodontitis groups.
Time frame
baseline2
Soluble MerTK (sMerTK) Levels in Gingival Crevicular Fluid
Quantitative measurement of soluble MerTK (sMerTK) levels (pg/mL) in gingival crevicular fluid samples using enzyme-linked immunosorbent assay (ELISA), and comparison of these levels among periodontally healthy, gingivitis, and periodontitis groups.
Time frame
baselineSecondary outcomes
1
Plaque Index
Measurement of plaque index (score) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
Time frame
baseline2
Probing Depth
Measurement of probing depth (mm) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
Time frame
baseline3
Clinical Attachment Loss
Measurement of clinical attachment loss (mm) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
Time frame
baseline4
Gingival Index
Measurement of gingival index (score) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
Time frame
baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov